Tofacitinib in Juvenile Idiopathic Arthritis
NCT07211932 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 58
Last updated 2025-11-26
Summary
This study aims to evaluate, using real-world clinical practice data, the efficacy of tofacitinib in improving the clinical control of juvenile idiopathic arthritis (JIA) after 12 months of treatment.
Conditions
- Juvenile Idiopathic Arthritis (JIA)
Interventions
- DRUG
-
Tofacitinib
Patients received tofacitinib for the treatment of juvenile idiopathic arthritis (JIA).
Sponsors & Collaborators
-
Consorci Sanitari de l'Alt Penedès i Garraf
lead OTHER
Eligibility
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-12-31
- Primary Completion
- 2026-12-31
- Completion
- 2026-12-31
Countries
- Spain
Study Locations
More Related Trials
-
A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis
NCT01904292 ·Status: COMPLETED ·Phase: PHASE1
-
ToFAcitinib in Early Active Axial SpondyloarThritis:
NCT06112665 ·Status: RECRUITING ·Phase: PHASE4
-
Real-world Effectiveness of Tofacitinib on Ulcerative Colitis Associated Spondyloarthropathy
NCT05431283 ·Status: UNKNOWN
-
Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)
NCT01844518 ·Status: COMPLETED ·Phase: PHASE3
-
Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
NCT01976364 ·Status: COMPLETED ·Phase: PHASE3
-
Predictors of Response to Tofacitinib Treatment in Rheumatoid Arthritis Patients
NCT04079920 ·Status: COMPLETED
-
Patient-Reported Outcomes In Rheumatoid Arthritis Patients Treated With Tofacitinib Or Biological Disease-Modifying Antirheumatic Drugs (DMARDs) In Real Life Conditions
NCT03073109 ·Status: COMPLETED
-
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
NCT05609630 ·Status: RECRUITING ·Phase: PHASE3
-
Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis
NCT02831855 ·Status: COMPLETED ·Phase: PHASE4
-
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
NCT06668181 ·Status: RECRUITING ·Phase: PHASE3
-
Study to Evaluate Safety and Effects of Tofacitinib and Biologic Disease Modifying Antirheumatic Drugs in People Treated for Rheumatoid Arthritis
NCT05572567 ·Status: COMPLETED
-
A Study To Describe The Use Of Tofacitinib After Use Of Rituximab In Patients With Rheumatoid Arthritis In A Real-World Setting
NCT05487703 ·Status: COMPLETED
-
A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
NCT03773978 ·Status: COMPLETED ·Phase: PHASE3
-
TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE
NCT04413617 ·Status: COMPLETED ·Phase: PHASE2
-
Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis
NCT01786668 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in Japan
NCT01835470 ·Status: COMPLETED ·Phase: PHASE3
-
A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis
NCT02281552 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)
NCT00642460 ·Status: COMPLETED ·Phase: PHASE3
-
Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis
NCT02087696 ·Status: UNKNOWN ·Phase: PHASE4
-
Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis
NCT01932372 ·Status: COMPLETED
-
Safety and Efficacy of Tofacitinib in the Treatment of NSAID Refractory Axial Spondyloarthritis:A Clinical Trial
NCT03738956 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
To Compare the Efficacy and Safety of Low-dose Glucocorticoids and Tofacitinib in Alleviating Moderate to High Disease Activity Rheumatoid Arthritis for 24 Weeks
NCT05606107 ·Status: UNKNOWN ·Phase: PHASE4
-
Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis
NCT06654882 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
NCT04088396 ·Status: RECRUITING ·Phase: PHASE3
-
Tofacitinib in the Treatment of Rheumatoid Arthritis-related Interstitial Lung Disease.
NCT05246293 ·Status: UNKNOWN ·Phase: PHASE2